These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 2137288)

  • 1. Visual compatibility of foscarnet with other injectable drugs.
    Lor E; Takagi J
    Am J Hosp Pharm; 1990 Jan; 47(1):157-9. PubMed ID: 2137288
    [No Abstract]   [Full Text] [Related]  

  • 2. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
    Baltz JK; Kennedy P; Minor JR; Gallelli J
    Am J Hosp Pharm; 1990 Sep; 47(9):2075-7. PubMed ID: 2145761
    [No Abstract]   [Full Text] [Related]  

  • 3. Additional data on visual compatibility of foscarnet sodium with morphine sulfate.
    DiStefano JE; Outman WR
    Am J Hosp Pharm; 1992 Jul; 49(7):1672. PubMed ID: 1535751
    [No Abstract]   [Full Text] [Related]  

  • 4. Visual compatibility of dobutamine hydrochloride with other injectable drugs.
    Hasegawa GR; Eder JF
    Am J Hosp Pharm; 1984 May; 41(5):949-51. PubMed ID: 6731457
    [No Abstract]   [Full Text] [Related]  

  • 5. Visual compatibility of zidovudine with other injectable drugs during simulated Y-site administration.
    Bashaw ED; Amantea MA; Minor JR; Gallelli JF
    Am J Hosp Pharm; 1988 Dec; 45(12):2532-3. PubMed ID: 3228107
    [No Abstract]   [Full Text] [Related]  

  • 6. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs.
    Lee CY; Mauro VF; Alexander KS
    Am J Hosp Pharm; 1990 Mar; 47(3):606-8. PubMed ID: 2107741
    [No Abstract]   [Full Text] [Related]  

  • 7. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
    Hasegawa GR; Eder JF
    Am J Hosp Pharm; 1984 Jul; 41(7):1379-80. PubMed ID: 6465154
    [No Abstract]   [Full Text] [Related]  

  • 8. Visual compatibility of hetastarch with injectable critical-care drugs.
    Wohlford JG; Fowler MD
    Am J Hosp Pharm; 1989 May; 46(5):995-6. PubMed ID: 2471410
    [No Abstract]   [Full Text] [Related]  

  • 9. More information on the visual compatibility of hetastarch with injectable critical-care drugs.
    Wohlford JG; Wright JC; Wilson MR
    Am J Hosp Pharm; 1990 Feb; 47(2):297-8. PubMed ID: 1689956
    [No Abstract]   [Full Text] [Related]  

  • 10. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
    Colucci RD; Cobuzzi LE; Halpern NA
    Am J Hosp Pharm; 1988 Jun; 45(6):1357-8. PubMed ID: 3414706
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir.
    Al-Samarai A; Kinghorn G; Potter C
    Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616
    [No Abstract]   [Full Text] [Related]  

  • 12. Foscarnet prophylaxis in marrow transplant recipients.
    Ringden O; Lonnqvist B; Aschan J; Sundberg B
    Bone Marrow Transplant; 1989 Nov; 4(6):713. PubMed ID: 2555006
    [No Abstract]   [Full Text] [Related]  

  • 13. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
    Forman JK; Souney PF
    Am J Hosp Pharm; 1987 Oct; 44(10):2298-9. PubMed ID: 3687973
    [No Abstract]   [Full Text] [Related]  

  • 14. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications.
    Souney PF; Solomon MA; Stancher D
    Am J Hosp Pharm; 1984 Sep; 41(9):1840-1. PubMed ID: 6496520
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Cytomegalovirus infection].
    Leport C; Salmon D
    Rev Prat; 1990 Feb; 40(6):566-7. PubMed ID: 2157272
    [No Abstract]   [Full Text] [Related]  

  • 16. Forscarnet-induced tubulointerstitial nephritis in renal transplant patients.
    Nyberg G; Blohmé I; Persson H; Svalander C
    Transplant Proc; 1990 Feb; 22(1):241. PubMed ID: 2137949
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet.
    Hedin G; Weiland O; Ljunggren K; Strömberg A; Nordenfelt E; Hansson BG; Oberg B
    Prog Clin Biol Res; 1987; 234():309-20. PubMed ID: 2957702
    [No Abstract]   [Full Text] [Related]  

  • 18. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
    Ahlmén J; Wijnween AC; Brynger H; Lycke E
    Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
    Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J
    J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.